ArticleTheranostics2020
A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.Frontiers in immunology · 2022Pooled it
- Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities.Human vaccines & immunotherapeutics · 2026Review
- Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review.The Lancet regional health. Western Pacific · 2026Review
- Case Report: Anti-PL-12 Antisynthetase syndrome complicated by natural killer/T cell non-Hodgkin's lymphoma.Frontiers in immunology · 2026Review
- Immunogenicity analyses and indirect ELISA application of a chimeric virus-like particle presenting a highly conserved peptide of Akabane virus Gc protein.Virology journal · 2025Article
- Review
- Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025Review
- A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection.Vaccines · 2025Article
- The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS.Heliyon · 2024Review
- A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection.Frontiers in immunology · 2024Article
- Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens.Vaccines · 2023Review
- A perspective on SARS-CoV-2 virus-like particles vaccines.International immunopharmacology · 2023Review
- Urgency and necessity of Epstein-Barr virus prophylactic vaccines.NPJ vaccines · 2022Review
- Review
- Article
- Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction.Vaccines · 2021Review
- Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses.Viruses · 2021Article
- Stress-Induced Epstein-Barr Virus Reactivation.Biomolecules · 2021Review
- The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.Frontiers in immunology · 2021Review
- Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Xiao ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Bingchun ZhaoState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Mingmei DingSchool of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
Shuo SongState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen, China.
Yinfeng KangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Yang YuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Miao XuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Tong XiangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Ling GaoState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Qisheng FengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Qinjian ZhaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, PR China.
Mu-Sheng ZengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Claude KrummenacherDepartment of Biological Sciences and Department of Molecular and Cellular Biosciences, Rowan University, Glassboro, NJ, United States.
Yi-Xin ZengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Sun Yat-sen University · CNSun Yat-sen University Cancer Center · CNXiamen University · CNNational Institute of Allergy and Infectious Diseases · USRowan University · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralEpitopesEpstein-Barr Virus InfectionsHerpesvirus 4, HumanImmunizationImmunoglobulin GMaleMiceMice, Inbred BALB CPeptidesRecombinant Fusion ProteinsVaccinationVaccinesViral Matrix ProteinsAntibodies, NeutralizingAntibodies, ViralEBV-associated membrane antigen, Epstein-Barr virusEpitopesImmunoglobulin GPeptidesRecombinant Fusion ProteinsVaccinesViral Matrix ProteinsChimeric virus-like particleConserved epitope peptideEnvelope glycoproteinEpstein-Barr virusgp350HBc149Neutralizing antibody.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.